Search research articles
Contact Us
Filters
Showing results (321-330 of 502) with videos related to
Page
of 51
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 6, 2018
Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update
Gregory P Kalemkerian, Navneet Narula, Erin B Kennedy, et al.
Cancer Immunology, Immunotherapy : CII
|
October 25, 2016
Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report
Taofeek K Owonikoko, Mukesh Kumar, Shu Yang, et al.
JTO Clinical and Research Reports
|
August 30, 2023
Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced <i>ALK</i>- or <i>ROS1</i>-Rearranged NSCLC: A Brief Report
Rohit Thummalapalli, Noura J Choudhury, Fiona Ehrich, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 15, 2026
Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study
Terufumi Kato, Xiaorong Dong, Toshiaki Takahashi, et al.
Cancer
|
December 5, 2018
Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies
Myung-Ju Ahn, Chun-Ming Tsai, Frances A Shepherd, et al.
Cancer
|
December 24, 2015
Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium
Conor E Steuer, Madhusmita Behera, Lynne Berry, et al.
Human Gene Therapy
|
September 30, 2010
A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase plasmid liposome protection in patients with locally advanced stage III non-small-cell lung cancer
Ahmad A Tarhini, Chandra P Belani, James D Luketich, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 22, 2026
Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy
Edurne Arriola, Ignacio Casarini, Mustafa Özgüroğlu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 1, 2011
Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003)
Suresh S Ramalingam, Angela M Davies, Jeffrey Longmate, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 17, 2015
ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer
Ramaswamy Govindan, Sumithra J Mandrekar, David E Gerber, et al.
Page
of 51
Search research articles
Search
Showing results (321-330 of 502) with videos related to
Sort By:
Page
of 51
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 6, 2018
Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update
Gregory P Kalemkerian, Navneet Narula, Erin B Kennedy, et al.
Cancer Immunology, Immunotherapy : CII
|
October 25, 2016
Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report
Taofeek K Owonikoko, Mukesh Kumar, Shu Yang, et al.
JTO Clinical and Research Reports
|
August 30, 2023
Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced <i>ALK</i>- or <i>ROS1</i>-Rearranged NSCLC: A Brief Report
Rohit Thummalapalli, Noura J Choudhury, Fiona Ehrich, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 15, 2026
Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study
Terufumi Kato, Xiaorong Dong, Toshiaki Takahashi, et al.
Cancer
|
December 5, 2018
Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies
Myung-Ju Ahn, Chun-Ming Tsai, Frances A Shepherd, et al.
Cancer
|
December 24, 2015
Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium
Conor E Steuer, Madhusmita Behera, Lynne Berry, et al.
Human Gene Therapy
|
September 30, 2010
A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase plasmid liposome protection in patients with locally advanced stage III non-small-cell lung cancer
Ahmad A Tarhini, Chandra P Belani, James D Luketich, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 22, 2026
Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy
Edurne Arriola, Ignacio Casarini, Mustafa Özgüroğlu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 1, 2011
Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003)
Suresh S Ramalingam, Angela M Davies, Jeffrey Longmate, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 17, 2015
ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer
Ramaswamy Govindan, Sumithra J Mandrekar, David E Gerber, et al.
Page
of 51